Vertex Pharmaceuticals Inc. shares dropped 0.23% to $199.59 Wednesday. This proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.46% to 4,402.66 and Dow Jones Industrial Average DJIA falling 0.92% to 34,792.67.
Vertex Pharmaceuticals Inc. closed $83.86 short of its 52-week high ($283.45), which the company achieved on September 2nd. Despite its losses, the stock outperformed some of its competitors Wednesday, as Johnson & Johnson JNJ fell 0.59% to $173.36, Merck & Co. Inc. MRK fell 1.22% to $75.48, and AbbVie Inc. ABBV fell 1.01% to $115.08.
Mr. Arbuckle has more than 30 years of experience leading global sales and marketing efforts at biopharmaceutical companies, including at Amgen and GlaxoSmithKline plc. Mr. Arbuckle currently serves as a member of Rhythm Pharmaceuticals and ImmunoGen’s board of directors, as a national board member of the Cancer Support Community, and on the Executive Committee and Health Section Governing Board for the Biotechnology Innovation Organization (BIO). He is also co-chair of the BIO Standing Committee on Access & Value. Mr. Arbuckle earned a degree in pharmacology and physiology from the University of Leeds in the United Kingdom.